MF研究者総覧

教員活動データベース

The changes in kynurenine metabolites induced by rTMS in treatment-resistant depression: A pilot study

発表形態:
原著論文
主要業績:
主要業績
単著・共著:
共著
発表年月:
2021年06月
DOI:
10.1016/j.jpsychires.2021.04.009
会議属性:
指定なし
査読:
有り
リンク情報:

日本語フィールド

著者:
○Hiroshi Tateishi, Daiki Setoyama, Dongchon Kang, Jun Matsushima, Ryohei Kojima, Yuka Fujii, Seiji Mawatari, Jun Kikuchi, Yuta Sakemura, Junko Fukuchi, Takumi Shiraishi, Toshihiko Maekawa, Takahiro A Kato, Toyoko Asami, Yoshito Mizoguchi, Akira Monji
題名:
The changes in kynurenine metabolites induced by rTMS in treatment-resistant depression: A pilot study
発表情報:
J Psychiatr Res 巻: 138 ページ: 194-199
キーワード:
Cognitive dysfunction; Kynurenine; Metabolomics; Repetitive transcranial magnetic stimulation (rTMS); Treatment-resistant depression (TRD)
概要:
Background: Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation technique that is considered a valuable and promising technique for improving depressive symptoms in treatment-resistant depression (TRD). However, the exact mechanism by which rTMS ameliorates depressive symptoms remains to be clarified. Objective: The aim of the present study was to analyzed the changes in metabolites of patients with TRD in the rTMS treatment, especially focusing on the kynurenine (KYN) pathway. Methods: Thirteen participants with TRD were enrolled in a high-frequency (10 Hz) rTMS study. Cognitive function, depressive symptoms and the concentration of plasma tryptophan (TRP) metabolites were measured at baseline and at the endpoint of rTMS treatment. Results: rTMS treatment significantly improved depressive symptom scores and some subscales of cognitive dysfunction. The present study has demonstrated that rTMS treatment significantly increased plasma TRP levels and significantly decreased plasma serotonin levels, while plasma KYN and kynurenic acid level as well as KYN/TRP ratio remained unchanged. Conclusions: This is the first metabolomic study of patients with TRD undergoing rTMS treatment. To validate the present results, it is necessary to increase the number of cases including controls, use a sample of cerebrospinal fluid, and measure blood concentration over time in the course of rTMS treatment.
抄録:

英語フィールド

Author:
○Hiroshi Tateishi, Daiki Setoyama, Dongchon Kang, Jun Matsushima, Ryohei Kojima, Yuka Fujii, Seiji Mawatari, Jun Kikuchi, Yuta Sakemura, Junko Fukuchi, Takumi Shiraishi, Toshihiko Maekawa, Takahiro A Kato, Toyoko Asami, Yoshito Mizoguchi, Akira Monji
Title:
The changes in kynurenine metabolites induced by rTMS in treatment-resistant depression: A pilot study
Announcement information:
J Psychiatr Res Vol: 138 Page: 194-199
Keyword:
Cognitive dysfunction; Kynurenine; Metabolomics; Repetitive transcranial magnetic stimulation (rTMS); Treatment-resistant depression (TRD)
An abstract:
Background: Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation technique that is considered a valuable and promising technique for improving depressive symptoms in treatment-resistant depression (TRD). However, the exact mechanism by which rTMS ameliorates depressive symptoms remains to be clarified. Objective: The aim of the present study was to analyzed the changes in metabolites of patients with TRD in the rTMS treatment, especially focusing on the kynurenine (KYN) pathway. Methods: Thirteen participants with TRD were enrolled in a high-frequency (10 Hz) rTMS study. Cognitive function, depressive symptoms and the concentration of plasma tryptophan (TRP) metabolites were measured at baseline and at the endpoint of rTMS treatment. Results: rTMS treatment significantly improved depressive symptom scores and some subscales of cognitive dysfunction. The present study has demonstrated that rTMS treatment significantly increased plasma TRP levels and significantly decreased plasma serotonin levels, while plasma KYN and kynurenic acid level as well as KYN/TRP ratio remained unchanged. Conclusions: This is the first metabolomic study of patients with TRD undergoing rTMS treatment. To validate the present results, it is necessary to increase the number of cases including controls, use a sample of cerebrospinal fluid, and measure blood concentration over time in the course of rTMS treatment.


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.